WAVE Life Sciences (NASDAQ:WVE) Announces Earnings Results

WAVE Life Sciences (NASDAQ:WVE) posted its earnings results on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.04), FiscalAI reports. The company had revenue of $2.27 million for the quarter, compared to the consensus estimate of $7.45 million. WAVE Life Sciences had a negative net margin of 309.73% and a negative return on equity of 52.61%.

Here are the key takeaways from WAVE Life Sciences’ conference call:

• WVE-007 obesity development advanced into Phase IIa with dosing underway in patients with higher BMI and comorbidities. The company is also planning combination-with-incretin and post-incretin maintenance studies this year, targeting fat loss with muscle preservation and potentially once- or twice-yearly dosing.
• WVE-006 produced data the company says support treatment of both lung and liver manifestations of AATD with infrequent subcutaneous dosing. The FDA granted a meeting expected later this summer to discuss a potential accelerated-approval pathway, while data from the 600 mg cohort are expected in the second half of 2026.
• Wave remains on track to submit a CTA for WVE-008 in PNPLA3 liver disease in 2026. The RNA-editing program aims to restore functional protein rather than silence the target, with preclinical data showing more than 50% editing and reduced lipid accumulation versus siRNA.
• The company is exploring partnerships for its DMD candidate WVE-N531 before filing an NDA, citing an evolving regulatory and commercial landscape. Management said it continues to believe in the program but will reassess filing plans based on regulatory developments and partnership progress.
• Second-quarter revenue fell to $2.3 million from $8.7 million a year earlier, while the net loss widened to $69.4 million from $50.5 million as R&D and G&A spending increased. Wave ended the quarter with $490.6 million in cash and expects funding into Q3 2028, excluding potential future GSK milestone payments.

WAVE Life Sciences Stock Performance

Shares of WVE stock traded down $0.25 during mid-day trading on Friday, reaching $5.51. 2,866,818 shares of the company’s stock traded hands, compared to its average volume of 2,174,352. The firm has a market capitalization of $1.06 billion, a PE ratio of -5.06 and a beta of -1.29. WAVE Life Sciences has a 12 month low of $5.02 and a 12 month high of $21.73. The firm has a 50 day moving average price of $5.98 and a two-hundred day moving average price of $8.98.

Key WAVE Life Sciences News

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: WAVE said dosing is underway in the Phase 2a multidose portion of its INLIGHT trial evaluating WVE-007, an INHBE GalNAc-siRNA treatment, in people with obesity and related conditions. The study could also support future development in MASH, type 2 diabetes and other cardiometabolic diseases. WAVE Life Sciences Second-Quarter Results and Business Update
• Positive Sentiment: Citigroup maintained a Buy rating despite lowering its price target from $24 to $19, implying significant potential upside from the current trading level. Benzinga analyst update
• Positive Sentiment: Wedbush also retained an Outperform rating while reducing its target from $15 to $12, indicating analysts remain constructive on WVE’s pipeline despite lower near-term valuation expectations. The Fly analyst update
• Negative Sentiment: Second-quarter adjusted loss was $0.34 per share, worse than the $0.31 consensus estimate and the $0.31 loss reported a year earlier. WAVE Life Sciences Q2 Earnings Report
• Negative Sentiment: Revenue of $2.27 million substantially missed analysts’ $6.53 million expectation, reinforcing concerns about the company’s limited current commercial revenue and ongoing losses. WAVE Life Sciences Earnings Report
• Negative Sentiment: The reductions in both analyst price targets suggest expectations for WVE’s near-term valuation have moderated, even though the firms kept bullish ratings.

Institutional Trading of WAVE Life Sciences

Several hedge funds have recently bought and sold shares of the stock. Smartleaf Asset Management LLC raised its stake in shares of WAVE Life Sciences by 645.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock worth $38,000 after buying an additional 1,942 shares during the period. Russell Investments Group Ltd. grew its stake in shares of WAVE Life Sciences by 1,441.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company’s stock valued at $73,000 after acquiring an additional 9,284 shares during the period. Tower Research Capital LLC TRC increased its holdings in WAVE Life Sciences by 44.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,658 shares of the company’s stock worth $76,000 after acquiring an additional 3,609 shares in the last quarter. Prudential Financial Inc. bought a new stake in WAVE Life Sciences during the 2nd quarter worth approximately $80,000. Finally, CIBC Bancorp USA Inc. bought a new stake in WAVE Life Sciences during the 3rd quarter worth approximately $87,000. Institutional investors own 89.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on WVE shares. Zacks Research upgraded shares of WAVE Life Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Wells Fargo & Company boosted their target price on shares of WAVE Life Sciences from $13.00 to $14.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Wall Street Zen cut WAVE Life Sciences from a “hold” rating to a “strong sell” rating in a report on Saturday. B. Riley Financial dropped their price target on WAVE Life Sciences from $31.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Canaccord Genuity Group cut their price objective on WAVE Life Sciences from $52.00 to $43.00 and set a “buy” rating for the company in a report on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $23.88.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.